StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > I'm guessing it's been quiet because...

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Apr 08, 2021 4:11pm

73 Views

Post# 32958539

RE:RE:I'm guessing it's been quiet because...

I thought you sold. Welcome back

cactuseskimo wrote: You forgot to add that it cratered 50% in price in two days and also had the analyst rating drop from 4.00 to 1.25 after a colossal dissapointment. It's like you're desperately trying to perfume a skunk's a$$ to try and hide the smell or something. Honestly, the stock may go up, and if it does, great. But these kind of posts are what creates "bashers" in the first place. They just get sick of the rose-colored glasses pumping BS.

gojotv! wrote: ...investors are checking their accounts to see what they can free up to buy more here.
I know that's what I did earlier today.
Good financials, growing profits, frugal management, recent reverse-split has shrunken the share float, first to market with a multi-cancer blood panel and the first couple of thousand patients already lined up, acquired our own source of demand and follow-up capacity, an employer group strategy in the works, a toehold in the rapidly growing telehealth market, the list goes on and on...
Very happy with my choice. It sure smells like money to me!
GLTAll Investors!